New cocktail aims to turn inoperable stomach cancer into operable
NCT ID NCT07353684
First seen Feb 01, 2026 · Last updated May 22, 2026 · Updated 19 times
Summary
This study tests whether a combination of four drugs (adebrelimab, apatinib, oxaliplatin, and tigio) can shrink advanced stomach or gastroesophageal junction cancer enough to allow surgical removal. About 49 adults with unresectable stage III or IV cancer will receive 2 to 8 cycles of treatment before surgery. The main goal is to see how many patients achieve a complete tumor removal with clear margins (R0 resection) and to monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADEBRELIMAB are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.